Janus Kinase Inhibitor as novel treatment of atopic dermatitis: A review
Keywords:
atopic dermatitis, janus kinase inhibitor, JAK-STAT pathway, psychological well-beingAbstract
Known as a multifactorial illness, atopic dermatitis (AD) affects up to 20% of children and 10% of adults and is characterized by chronic inflammatory skin conditions. However, the whole pathophysiology of AD has not yet been completely understood. Janus kinase (JAK) inhibitors have recently become a novel therapeutic approach for the treatment of AD. The STAT (signal transducer and activator of transcription) transcription factor is phosphorylated after the transphosphorylation of the JAK receptor, which activates the JAK receptor. Following dimerization, STAT moves into the cell nucleus to alter gene transcription. Inhibition of JAK receptors prevents their transphosphorylation, which in turn prevents STAT's phosphorylation and dimerization, eventually prevents the production of inflammatory cytokines and dampens the inflammatory response as a whole. Differing JAK inhibitors with various isotype specificities have been created recently. By focusing on JAK signaling molecules downstream, JAK inhibitors in the context of AD can target a number of pruritogenic pathways. Consequently, oral and topical JAK inhibitors are viewed as novel AD treatments, particularly for individuals with persistent pruritus. In conclusion, JAK inhibitor are a potential new therapy option for AD and have been shown in several trials to be successful in symptom relief, improving quality of life, and enhancing psychological well-being of patients. Despite the encouraging results, further research is required to gauge the effectiveness and safety of JAK inhibitors.References
Le M, Berman-Rosa M, Ghazawi FM, Bourcier M, Fiorillo L, Gooderham M, et al. Systematic review on the efficacy and safety of oral janus kinase inhibitors for the treatment of atopic dermatitis. Frontiers. 2021. https://doi.org/10.3389/fmed.2021.682547.
Kolb L, Ferrer-Bruker SJ. Atopic Dermatitis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448071/#_NBK448071_pubdet_.
Cartron AM, Nguyen TH, Roh YS, Kwatra MM, Kwatra SG. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820-824. Doi:10.1111/ced.14567
Simpson E, Leung D, Eichenfield L, Boguniewicz M. Atopic Dermatitis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 9th ed. United States: McGraw-Hill; 2019. P. 363–81.
Le M, Berman-Rosa M, Ghazawi FM, Bourcier M, Fiorillo L, Gooderham M, Guenther L, Hanna S, Hong HC-H, et al. Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Front. Med. 2021. 8:682547. doi: 10.3389/fmed.2021.682547.
Umborowati MA, Damayanti D, Anggraeni S, et al. The role of probiotics in the treatment of adult atopic dermatitis: a meta-analysis of randomized controlled trials. J Health Popul Nutr. 2022; 41: 37.
Umborowati MA, Salsabila NW, Damayanti D, Angraeni S, Prakoeswa CRS. The role of skin and gut microbiome in atopic dermatitis. J Pak Assoc Dermatol. 2022, 32: 1.
Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergologie Select. 2021;5(01):293–304.
Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. ImmunoTargets and Therapy. 2020; 9: 255–72.
Kim J, Kim BE, Leung DY. Pathophysiology of atopic dermatitis: Clinical implications. Allergy and Asthma Proceedings. 2019;40(2):84–92.
Kim K, Kim H, Sung GY. An Interleukin-4 and Interleukin-13 Induced Atopic Dermatitis Human Skin Equivalent Model by a Skin-On-A-Chip. Int J Mol Sci. 2022; 23(4):2116. https://doi.org/10.3390/ijms23042116.
Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16: 843–62.
Damsky W, Peterson D, Ramseier J, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021; 147: 814–26.
Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017; 13: 234–43.
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175 (5): 902–11. doi:10.1111/bjd.14871.
Incyte Corporation. Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis [press release]. Wilmington, DE: Incyte Corporation; 2020.
Herwanto N, Hutomo M. Retrospective Study: Management of Atopic Dermatitis. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2016; 28(1): 49–58. doi: 10.20473/bikk.V28.1.2016.49-58.
Ratnaningtyas WD, Hutomo M. Topical Therapy in Atopic Dermatitis Patient. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2017; 28(3): 210–16. doi: https://doi.org/10.20473/bikk.V28.3.2016.210-216
Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. doi:10.1016/j.jaci.2019.11.025.
Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921. e919. doi:10.1016/j.jaad.2018.01.018.
He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192. doi:10.1007/ s40257-018-0413-2
Verden A, Dimbil M, Kyle R, Overstreet B, Hoffman KB. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357–361. doi:10.1007/s40264-017-0622-2.
Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019;181 (4):733–742. doi:10.1111/bjd.17932.
